Immunic Q2 2026 net loss $34.1M; ENSURE top-line data expected by year-end; Ridloff joins board

IMMUNIC, INC.

2026-Q2 EPS reported -$1.83

Q2 2026 net loss $34.1M ($0.80/share) vs $26.8M ($2.03/share) in Q2 2025; R&D spend $25.9M.
Cash and equivalents $155.1M at June 30, 2026; expected to fund operations into late 2027.
Phase 3 ENSURE relapsing MS top-line data expected by end of 2026; NDA submission mid-2027 if positive.
Elena Ridloff appointed to Board Aug 6, 2026; received options for 50,740 shares.
Daniel Vitt resigned from Board; separation agreement provides $670K lump sum, $276K bonus, 100% equity vesting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.